Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks [Yahoo! Finance]
Definium Therapeutics, Inc. - Common Shares (DFTX)
Company Research
Source: Yahoo! Finance
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Definium Therapeutics' lead asset, DT120 ODT, has received FDA Breakthrough Therapy Designation for generalized anxiety disorder. The company is preparing for potential commercialization by building out commercial capabilities, strengthening its balance sheet, and adding to its leadership team. Multiple pivotal Phase III readouts for DT120 ODT are expected in 2026 across large psychiatric indications. For investors watching NasdaqGS:DFTX, this update goes well beyond routine quarterly numbers. The stock closed at $17.45, with the share price up 27.9% year to date and 159.7% over the past year, while the 5 year return sits at a 59.3% decline. That mix of strong recent performance and weaker long term results makes the current news flow around DT120 ODT especially important to track. FDA Breakthrough Therapy Designation can signal a mor
Show less
Read more
Impact Snapshot
Event Time:
DFTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DFTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DFTX alerts
High impacting Definium Therapeutics, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
DFTX
News
- Definium Therapeutics (DFTX) had its price target raised by HC Wainwright from $55.00 to $70.00. They now have a "buy" rating on the stock.MarketBeat
- Definium Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates [Yahoo! Finance]Yahoo! Finance
- Definium Therapeutics Reports Full-Year 2025 Financial Results and Business UpdatesBusiness Wire
- Definium Therapeutics (DFTX) was upgraded by Wolfe Research to "strong-buy".MarketBeat
DFTX
Earnings
- 2/26/26 - Miss
DFTX
Sec Filings
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- DFTX's page on the SEC website